Immunotherapy of breast cancer at an early stage of the disease increases the likelihood of success. Here, in a mouse model, we report a new strategy that enables vaccines to be prepared from microgram amounts of tumor tissue. The vaccine is prepared by transfer of a cDNA expression library from relatively small numbers of breast cancer cells into a highly immunogenic cell line, where genes specifying TAA are expressed. As the transferred DNA is integrated and replicated as the recipient cells divide, the number of vaccine cells can be conveniently expanded for repeated immunizations. A cDNA expression library prepared from a breast cancer that arose spontaneously in a C3H/He mouse (H-2 k ) was transferred into a mouse fibroblast cell line derived from C3H/He mice. To augment their nonspecific immunogenic properties, the fibroblasts were genetically modified before DNA transfer to secrete IL-2 and to express allogeneic MHC class I H-2K b -determinants. C3H/He mice, highly susceptible to growth of the breast cancer cells, were immunized with the cDNA-transfected cells. Robust breast cancer-specific CD8 þ T-cell-mediated immunity was generated in the mice, raising the possibility that an analogous treatment strategy could be used to treat breast cancer patients at an early stage of the disease.
A lthough experimental protocols in mice are revealing the potential of immunotherapy in cancer treatment, successful vaccination strategies in cancer patients are wanting. One possible explanation is that even though the immune system can adversely affect diffuse and smaller tumors, it cannot effectively destroy large, established neoplasms. An immunotherapeutic strategy that would allow vaccines to be prepared from microgram amounts of autologous tumor tissue would enable treatment to begin at an early stage before the tumor became large, bulky and widely disseminated.
Like other neoplasms, breast cancer cells form weakly immunogenic TAA. Under appropriate circumstances, they can be recognized by CTLs. 1, 2 The antitumor immune responses following immunization with effective vaccines can be of sufficient magnitude to prolong the lives of experimental animals, and patients, providing a compelling rationale for the use of tumor vaccines in cancer therapy. 3, 4 In breast cancer, TAA such as MUC-1, 5 HER-2/neu, 6 MAGE-1, 7 BAGE, 8 mammaglobin 9 and MENA 10 have been identified as potential targets of CTLs. It is likely that these are only several representations of an undefined, and possibly large number of TAA expressed by breast cancer cells. Malignant cells are notoriously genetically unstable. 11 Breast cancer cells are the richest source of tumorspecific TAA. The use of whole tumor cells as vaccines avoids the need for immunizations with defined TAA. When successful, whole tumor cell vaccines can induce immunity to multiple TAA expressed by the cancer cells. To augment their inherent weakly immunogenic properties, vaccines have been prepared by introducing expression-competent genes encoding foreign MHC antigens, 12 costimulatory or adhesion molecules, 13, 14 or cytokines 15, 16 into the patient's malignant cells. Gene-modified tumor cell vaccines were efficient stimulators of specific antitumor immune responses in animal models.
Vaccines have also been prepared by introducing tumor cell derivatives into dendritic cells (DCs), where TAA are expressed. 17, 18 Antitumor immune responses were induced in mice immunized with DCs pulsed with unfractionated tumor-derived peptides, 19 cell lysates, 20 mRNA 21, 22 or apoptotic cell bodies. 23, 24 These approaches, however, may require substantial quantities of tumor tissue, restricting their use to patients with relatively large cancer burdens.
In this study, we investigated a novel alternative approach. It was designed to enable the vaccine to be prepared from microgram amounts of tumor tissue. The vaccine was prepared by transfer of a cDNA expression library derived from relatively small numbers of breast cancer cells into a highly immunogenic fibroblast cell line where TAA were expressed. As the transferred cDNA is integrated into cellular DNA, and replicated as the recipient cells divide, the number of vaccine cells could be conveniently expanded in vitro for repeated immunizations.
Here, the vaccine was prepared by transfer of a cDNA expression library into LM cells, a mouse fibroblast cell line. The cDNA library was derived from 10 7 breast cancer cells (equivalent to a tumor of approximately 4 mm) from a neoplasm that arose spontaneously in a C3H/He mouse. The fibroblasts of C3H/He mouse origin (H-2 k ) were modified to secrete IL-2 and to express allogeneic MHC class I-determinants (H-2K b ). We reasoned that genes specifying numerous, undefined, weakly immunogenic TAA would be expressed in a highly immunogenic form by the transfected fibroblasts. Paracrine secretion of IL-2 and the expression of allogeneic MHC class I-determinants by the vaccine would enhance the development of the antitumor CTL response. The cDNA libraries were stable and readily amplified. Introduction of the library into the fibroblasts was conveniently accomplished.
The results indicated that immunization of C3H/He mice highly susceptible to the growth of the breast cancer cells with fibroblasts transfected with the cDNA expression library resulted in the induction of robust T-cellmediated immune responses directed toward the breast cancer cells. The induced immunity was sufficient to deter tumor growth. In some instances, the immunized mice appeared to have rejected the breast cancer cells and survived indefinitely.
Materials and methods

Animals and cells
Pathogen-free C3H/He mice (H-2 k ), 8-12-week-old, from the Charles River Laboratories (Wilmington, MD) were maintained in the animal care facilities of the University of Illinois, according to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The experimental protocol was reviewed and approved by the Animal Care Committee of the University of Illinois College of Medicine. SB5b cells were derived from an adenocarcinoma of the breast that arose spontaneously in a C3H/He mouse in our animal facility. LM cells, a fibroblast cell line of C3H/He mouse origin, and C3H/ MCA cells, a mouse fibrosarcoma cell line, were from the American Type Culture Collection (Manassas, VA). SCCVII cells, a moderately well-differentiated squamous carcinoma cell line derived from a tumor that arose spontaneously in a C3H/He mouse, were from T Whiteside (University of Pittsburgh, Pittsburgh, PA). B16F1 cells were a melanoma cell line from a neoplasm that originated in a C57BL/6 mouse (from I Fidler, M.D. Anderson, Houston, TX). All the cell cultures were maintained at 371 in a humidified 7% CO 2 /air atmosphere in DMEM (GIBCO BRL, Grand Island, NY) supplemented with 10% FBS (Sigma, St Louis, MO) and antibiotics (Life Technologies, Grand Island, NY).
Modification of LM fibroblasts to secrete IL-2
As a means of augmenting their nonspecific immunogenic properties, the fibroblasts used as recipients of cDNA from the breast cancer cells were modified to secrete IL-2 using a replication-defective retroviral vector (pZipNeoS-VIL-2, from MKL Collins, University College, London) as described previously. 25 Modification of LM fibroblasts to express MHC class I H-2K b -determinants
As an additional means of augmenting their immunogenic properties, the fibroblasts were modified before transfection to express allogeneic class I-determinants using a plasmid (pBR327H-2K b Biogen Research, Cambridge, MA) encoding MHC H-2K b as described previously.
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Preparation of cDNA libraries from SB5b breast cancer and B16F1 melanoma cells
Guanidine isothiocyanate was used to recover total RNA from SB5b breast or B16F1 melanoma cells (used as a specificity control) from in vitro culture. The mRNA, derived from 1 Â 10 7 cells, was isolated using an mRNA isolation system (Promega, Madison, WI). The cDNA expression libraries were constructed with a Lambda Zap vector using a cDNA library kit (Stratagene, La Jolla, CA), according to the manufacturer's instructions. In brief, cDNAs greater than 0.5 kb were selected by size fractionation via gel filtration and directionally cloned into a pBK-CMV vector with an EcoRI restriction site at b cells divided into four 100-mm plastic cell culture dishes 24 hours previously. After 18 hours, the cells were divided into sixteen 100-mm dishes and incubated for 14 days in a fresh growth medium containing 5 mg/ml blasticidin and 500 mg/ml G418. The surviving blasticidin/G418-resistant cells (at least 2.6 Â 10 5 colonies in each instance) (LM-IL-2K b /cSB5b or LM-IL-2K b /c B16F1 cells, respectively) were pooled and maintained as cell lines for use in the experiments. As a control, the same procedure was followed except that the fibroblasts were transfected with pcDNA6/Bla alone (LM-IL-2K b cells).
Spleen cell-mediated cytotoxicity determination
Mononuclear cells from the spleens of C3H/He mice immunized with LM-IL-2K b /cSB5b or LM-IL-2K b /c B16F1 cells were isolated by Ficoll-Hypaque density centrifugation. After washing, the cells were cocultured at 371 with mitomycin C-treated (45 min, 50 mg/ml mitomycin C) SB5b cells for 5 days (ratio of spleen cells:SB5b cells ¼ 30:1), as previously described. 27 Afterward, the population that failed to adhere to the plastic cell culture flasks was collected and used as effector cells for cytotoxicity determinations against the breast cancer cells. Spleen cell-mediated cytotoxic activity was measured in a standard 4-hour 51 Cr-release assay, using 51 Crlabeled SB5b cells as targets. The spontaneous release of isotope was determined by measuring the radioactivity released from an equivalent number of 51 Cr-labeled SB5b cells alone during the 4-hour period of incubation at 371. The maximum release of isotope was measured by determining the radioactivity released by an equivalent number of 51 Cr-labeled SB5b cells treated with a cell lysing solution (2% v/v Triton X-100 in distilled water). The percent-specific cytolysis was calculated as: In vitro depletion of T-cell subsets and NK cells
MAbs for T-cell subsets and NK cells were used to identify the cell types activated for antitumor cytotoxicity in mice immunized with the various cell constructs, as previously described. 28 Briefly, mononuclear cells were recovered from the spleens of C3H/He mice injected s.c. and i.p. with 2 Â 10 6 LM-IL-2K b /cSB5b or LM-IL-2K b /c B16F1 cells. The mononuclear cells were restimulated in vitro by coculture with mitomycin C-treated SB5b cells for 5 days. Afterward, the nonadherent cells were collected and incubated at 41C for 1 hour with anti-CD4 (L3T4) (hybridoma GK1.5), anti-CD8 (Lyt-2.2) (hybridoma 3.155) or anti-NK (NK1.1) (hybridoma PK136) mAbs followed by the addition of low-toxicity baby rabbit complement (Pel Freeze, Rogers, AR), and further incubation at 371 for 45 minutes. The antibodies were titered such that the concentration used was five times the minimal amount required to saturate the specific binding sites of spleen cells from naive C3H/He mice, as determined by cytofluorometric analyses of serially diluted antibodies. After depletion of the specific cell types in the spleen cell suspensions, cytotoxic activities were determined in a 4-hour 51 Cr-release assay against SB5b cells at various E:T ratios. An analysis by immunofluorescence of spleen cell populations after mAb treatment indicated that greater than 95% of the specific T-cell subsets were depleted with no decrease in the frequency of other cell types.
Immunization of C3H/He mice with modified fibroblasts transfected with cDNA library from SB5b breast cancer cells (LM-IL-2K b /cSB5b cells)
The immunogenic properties of LM-IL-2K
b /cSB5b cells against the breast cancer cells were tested in C3H/He mice. The mice received two s.c. and i.p. injections at weekly intervals of 2 Â 10 6 LM-IL-2K b /cSB5b cells at each injection site. As a control, the same protocol was followed except that the mice were injected with LM-IL-2K b /c B16F1 cells rather than LM-IL-2K b /cSB5b cells. At 1 week later after the last injection, mice in either group were injected into the fat pad of the breast with 1 Â 10 5 viable SB5b cells. The rate of increase in tumor volume and survival was determined. Tumor growth was measured three times weekly in two dimensions (length and width) with a vernier caliper. Tumor volume was calculated according to the formula: (width) 2 Â length Â 0.52 and reported as cm 3 . The median survival time (MST7SE) of tumor-bearing mice in each group was determined by life-table methods and by log-rank analysis.
Depletion of T-cell subsets in mice immunized with the transfected cells
To further identify the types of cells mediating tumor resistance in mice immunized with the transfected cells, the animals were injected i.p. with the Ab-rich fraction of ascitic fluid containing anti-CD8 (83-23-5 mouse hybridoma) or anti-CD4 (GK1.5 rat hybridoma) mAbs (both from K Herald, University of Illinois at Chicago). The antibody injections began 1 week before the challenging injection of SB5b cells. The mice received further injections of the relevant mAb every other day after the injection of SB5b cells for three additional injections, and then once per week thereafter. In total, 0.3 ml (5 mg) of enriched 83-12-5 Abs or 0.2 ml (1 mg) of enriched GK1.5 Abs was administrated at each injection. The efficiency and effectiveness of T-cell depletion were measured by cytofluorometric analysis of spleen cell suspensions taken 6 days after injection of the ascitic fluid. More than 93% depletion of the relevant T-cell subset was achieved, while maintaining normal levels of the other subset.
Immunofluorescent staining and cytofluorometric measurements
Quantitative immunofluorescence was used to measure the expression of MHC class I-and B7.1-determinants by the fibroblasts used as recipients of cDNA from the breast cancer cells. The determinations were performed cDNA-transfected fibroblasts as cancer vaccine T Sung Kim and EP Cohen in an Epic V flow cytofluorograph (Coulter Electronics, Hialeah, FL) equipped with a multiparameter data acquisition and display system (MDADS), as described previously.
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Mouse IFN-g ELISPOT assays ELISPOT IFN-g assays were used to detect the presence of spleen cells responsive to SB5b cells in mice immunized with the modified fibroblasts transfected with a cDNA library from the breast cancer cells. Responder T cells derived from the spleens of C3H/He mice immunized with LM-IL-2K b /SB5b cells were added to individual wells (1 Â 10 6 cells per well in 0.2 ml growth medium) of 96-well ELISPOT IFN-g plates (B-D Pharmingen, ELISPOT Mouse IFN-g Set). The plates were coated with 100 ml of the capture Ab (5 mg/ml in PBS). Stimulator SB5b beast cancer cells were then added at a responder:stimulator ratio of 10:1. After incubation for 18 hours at 371, the cells were removed by washing with PBS-Tween (0.05%). Detection antibodies (2 mg/ml) were then added to each well. The plates were incubated for 2 hours at room temperature and the washing steps were repeated. Afterward, streptavidin-peroxidase (streptavidin-HRP, 5 mg/ml) was added to the individual wells and the plates were washed four times with PBS-Tween and twice with PBS. Then, 100ml of aminoethylcarbazole staining solution was added into each well to develop the spots. The reaction was stopped after 4-6 minutes with deionized water. The spots were counted by computer-assisted image analysis (ImmunoSpot Series 2 analyzer: Cellular Technology Limited, Cleveland, OH). The coefficient of variation for the assay was o0.15% (n ¼ 50).
Statistical analyses
Life-table methods and log-rank analyses were used to determine the statistical differences between the survival of mice immunized with the various cell constructs. Student's t-tests and one-way ANOVA were used to determine the statistical differences in cytotoxic activities between various experimental and control groups. Po.05 was considered significant.
Results
Modification of LM mouse fibroblasts for the secretion of IL-2 and the expression of H-2K b class I-determinants
A multistep approach was used to prepare the vaccine. For the first step, a plasmid (pZipNeoSVIL-2), which specified human IL-2 along with a gene that conferred resistance to the neomycin analog G418, was introduced into the fibroblasts. After selection in medium containing sufficient quantities of G418 to kill 100% of nontransduced cells, the surviving, antibiotic-resistant cells were analyzed for IL-2-secretion. An IL-2-specific ELISA was used for this purpose. The results (Fig 1a) indicated that 1 Â 10 6 transduced fibroblasts formed 3.86 ng IL-2/48 hours. Culture supernatants of fibroblasts transduced with the IL-2-negative vector pZipNeoSV(X), which conferred antibiotic resistance alone, failed to contain detectable quantities of IL-2. IL-2-secretion by fibroblasts transduced with pZipNeoSVIL-2 was a stable property of LM mouse fibroblasts were transduced with a plasmid specifying human IL-2 and a neo r gene, used for selection. After 14 days, the cells were cultured in growth medium containing G418. The antibiotic-resistant cells were pooled and maintained as a cell line. Cell culture supernatants were collected after 48 hours incubation in growth medium from 10 6 cells (initial assay) and from 10 6 cells from a cell culture that had been maintained for more than 3 months (subsequent assay). The levels of IL-2 were determined by a sandwich ELISA, using mAb for IL-2. The values represent means7SD of triplicate determinations. (b) Expression of MHC class I-and B7.1-determinants: 1 Â 10 5 genetically modified fibroblasts were incubated for 1 hour at 41C with PE-conjugated anti-H-2K k or PE-conjugated anti-H-2K b mAbs. After incubation, the cells were washed and then analyzed for fluorescent staining. The same procedure was followed to detect the expression of B7.1-determinants except that FITC-conjugated anti-mouse B7.1 mAbs were substituted for mAbs for the class I-determinants. Dark-shaded area: cells stained with PE-conjugated anti-mouse H-2K k or anti-mouse H-2K b -determinants, or with FITC-conjugated anti-mouse B7.1 mAbs; unshaded area: cells incubated with PE-or FITC-conjugated isotype serum.
cDNA-transfected fibroblasts as cancer vaccine T Sung Kim and EP Cohen the cells. Equivalent amounts were detected in the culture supernatants after more than 3 months of continuous culture. Furthermore, the introduction of cDNA expression libraries into LM-IL-2 cells did not affect the levels of IL-2 secretion by the modified cells. As indicated (Fig 1a) , b class I-determinants was introduced into the cells, along with a puromycin-resistance plasmid (pBabePuro), used for selection. After incubation in medium containing sufficient quantities of puromycin to result in the death of 100% of nontransduced cells, the surviving antibioticresistant fibroblasts were pooled and maintained as a cell line. Quantitative immunofluorescent analysis of transfected fibroblasts stained with PE-conjugated mAbs for H-2K b -determinants was used to measure the expression of H-2K b -determinants. As a control, PE-labeled IgG2a isotype serum was substituted for PE-conjugated mAbs for H-2K b -determinats. As indicated (Fig 1b) , the specific immunofluorescence of IL-2-secreting fibroblasts transfected with the H-2 b -specifying plasmid was significantly higher than that of IL-2-secreting fibroblasts transfected with pBabePuro alone (log MFI values 0.32 and 0.98, respectively). The MFI of fibroblasts transfected with pBabePuro alone was approximately the same as fibroblasts stained with PE-conjugated IgG2a isotype serum.
To further characterize the cells used as cDNA recipients, the fibroblasts were stained with PE-conjugated anti-H-2K k or with FITC-conjugated anti-B7.1 mAbs. As indicated (Fig 1b) , the fibroblasts expressed both H-2 k and the costimulatory molecule B7.1 constitutively. Like IL-2-secretion, the introduction of cDNA expression libraries from SB5b breast cancer cells (or from B16F1 melanoma cells) into the modified fibroblasts had no significant effect upon the expression of the membrane-associated determinants (Fig 1a and b) . b /cB16F1 cells, followed by the challenging injection of SB5b cells. As indicated (Fig 2) , the time to the first 
Immunization of C3H/He mice with LM-IL-2K
b /cSB5b cells resulted in the generation of spleen cells responsive to the breast cancer cells ELISPOT IFN-g and 51 Cr-release assays were used to detect the presence of spleen cells responsive to SB5b cells in mice immunized with the transfected fibroblasts. As indicated (Fig 3a) , the number of spots in the group immunized with LM-IL-2K b /cSB5b cells, followed by coincubation of spleen cells from the immunized mice with SB5b cells was significantly higher (Po.001) than the number of spots in the control group immunized with LM-IL-2K b /cB16F1 cells, followed by coincubation with SB5b cells.
The same protocol was followed to measure spleen cell-mediated cytotoxic activity toward SB5b cells in the immunized mice. The results (Fig 3b) indicated that the percent-specific release of isotope was significantly higher in the group of mice immunized with LM-IL- b /cSB5b cells. At 1 week after the second immunization, spleen cell-mediated cytotoxicity determinations toward SCCVII squamous carcinoma cells and C3H/ MCA fibrosarcoma cells were compared with the response toward SB5b cells. As indicated (Fig 4) , the cytotoxic response toward SB5b cells exceeded the response toward either of the other cell types. As additional controls, C3H/He mice were immunized according to the same schedule with LM, LM-IL-2K b or LM-IL-2K b /cB16F1 cells, or the mice were injected with PBS. At 1 week after the second injection, spleen cellmediated cytotoxic activity toward SB5b cells was determined. As indicated (Fig 4a and b) , the cytotoxic activity of the greatest magnitude was in the group immunized with modified fibroblasts transfected with cDNA library from the breast cancer cells (Po.05).
Immunization with LM-IL-2K
b /cB16F1 cells stimulated cytotoxic activity toward SB5b cells, but to a lesser extent (Fig 4b) .
Thus, the immunity in mice immunized with modified fibroblasts transfected with a cDNA expression library As a means of determining the cell type(s) activated toward the breast cancer cells in the immunized animals, spleen cell populations from mice immunized with the transfected cells were depleted of CD8, CD4 or NK 1.1 cells before the cytotoxicity determinations were performed.
As indicated (Fig 5) , treatment of mice immunized with modified fibroblasts transfected with a cDNA library from the breast cancer cells with anti-CD8 mAb reduced the cytotoxic activity toward SB5b cells to the greatest extent. Treatment with anti-CD8 mAb had no significant effect upon spleen cell-mediated cytotoxicity toward T and CD4 þ T cells in resistance to tumor growth. As indicated (Fig 6a) , the survival of mice immunized with LM-IL-2K b /cSB5b cells depleted of CD8 þ cells was significantly less than that of nondepleted mice. Depletion of CD4 þ cells had no significant effect on the survival of immunized mice with breast cancer.
An analysis of the CTL activity toward SB5b cells in mice depleted of CD8 þ T cells were consistent with the reduced survival of tumor-bearing mice. As indicated (Fig 6c) , depletion of CD8 þ T cells, but not CD4 þ T cells, in C3H/He mice immunized with LM-IL-2K b /SB5b cells significantly reduced the cytotoxic activity toward the breast cancer cells.
Discussion
The extraordinarily high incidence of breast cancer in women, approximately one in eight will develop the disease at some point in her life, emphasizes the need for more effective forms of therapy. As a result of mass screening and earlier diagnosis, the prognosis for breast cancer patients has improved. Nevertheless, as many as one-half of patients whose disease appears to be nonmetastatic at diagnosis will relapse and one-third with die from metastatic disease. 30 Early diagnosis and treatment increases the likelihood of success.
Immunotherapeutic approaches are designed to stimulate immunity to autologous tumor. They are under active investigation for a number of different types of neoplastic diseases, including breast cancer. The rationale is that like types of cancer, breast cancer cells form unique T-cell epitopes. HER-2/neu, MUC-1, p53, among others, are potential targets of immune-mediated attack. Under ordinary circumstances, however, TAA expressed by proliferating breast cancer cells are insufficiently immunogenic. They fail to provoke an immune response that is capable of controlling tumor growth. This is especially the Here, we tested a novel vaccine that has certain advantages. The vaccine was prepared by transfer of a cDNA expression library derived from an aggressive breast cancer into a highly immunogenic mouse fibroblast cell line. The cDNA was prepared from relatively small numbers of cancer cells, equivalent to a tumor of approximately 4 mm. The long-term objective is to develop a treatment strategy that can be applied to breast cancer patients with minimal residual disease after primary therapy. The approach used was an application of classic studies indicating that the introduction of DNA from one cell type into another can result in stable integration of the transferred DNA and alteration of both the genotype and the phenotype of the recipient cells. [31] [32] [33] [34] As the transferred DNA is replicated as the recipient cells divide, the number of vaccine cells could be conveniently expanded to numbers sufficient for repeated immunizations. We reasoned that an array of weakly immunogenic tumor antigens formed by the breast cancer cells would become strongly immunogenic if they were expressed by highly immunogenic cells. cDNA, rather than genomic DNA, was chosen to exclude noncoding sequences from the vaccine and to enrich the transfected cell population for cells that express TAA.
Mouse fibroblasts, rather than dendritic cells, were chosen as the recipients of DNA from the cancer cells for several compelling reasons. Like dendritic cells, fibroblasts are efficient antigen-presenting cells. [35] [36] [37] [38] [39] The fibroblasts used in this study constitutively expressed MHC class I-determinants and costimulatory molecules required for T-cell activation. Among other advantages, the use of a fibroblast cell line enabled the cells to be modified in advance of cDNA transfer to augment their immunogenic properties. The cells were modified to secrete IL-2, and to express allogeneic MHC determinants. In addition to their properties as an adjuvant, the presence of allogeneic MHC determinants ensured that the vaccine would be rejected. There is a theoretical concern that a tumor derived from the vaccine itself might develop. In no instance has this been observed, nor have other toxic effects such as the appearance of an autoimmune disease been seen in the immunized mice. Our prior experience (unpublished), based on detection by PCR of the neo r gene included in the vector used to modify the cells for IL-2-secretion, is that the vaccine could no longer be detected 14 days after injection.
The results indicated that C3H/He mice immunized with the transfected fibroblasts developed robust, cellmediated immune responses toward the breast cancer cells that were capable of deterring tumor growth. The immunity was directed toward the type of cells from which the cDNA was obtained, but not against either of two noncrossreactive neoplasms originating in C3H/He mice.
We conclude that an array of undefined breast cancerassociated antigens was expressed in a highly immunogenic form by the transfected cells. The results raise the possibility that a vaccine useful in cancer therapy can be prepared by transfection of human fibroblasts with a cDNA expression library from the patient's malignant cells. Ideally, to provide a restriction element for direct antigen presentation, the patient and the cells used as cDNA recipients should share identity at one or more MHC class I-determinants. As the antigenic properties of each patient's neoplasm is likely to contain both common and unique TAA, to encompass the array of antigens that characterize the patient's cancer, the vaccine should be prepared with cDNA derived from the autologous tumor.
